Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Two-Year POETYK PsA-2 Data Show Durable Deucravacitinib Responses in Psoriatic Arthritis

17 September 2026 · By · Wire by Fusion42

Published

17 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at dermatologytimes.com →

◆ Verified

Fusion42 · 18 September 2026 · Fusion42 review

Two-year POETYK PsA-2 trial data demonstrated that deucravacitinib maintains durable clinical responses and a consistent safety profile in adults with active psoriatic arthritis, supporting its sustained use following FDA approval.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You can leverage deucravacitinib’s validated long-term efficacy to build trust with rheumatologists and patients as a reliable oral treatment in psoriatic arthritis. Expect increasing demand for therapies that combine joint and skin symptom control without new safety concerns.

◆ Coverage

1 source · 17 Sep 2026

◆ Related on Wire

◆ Topics

Biotechpsoriatic-arthritisdeucravacitinibclinical-triallong-term-efficacytyk2-inhibitor